Salute e Benessere

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7%…

The Red Biotechnology Market is driven by several factors that contribute to its growth. One of the key drivers is the increasing prevalence of chronic diseases. Chronic diseases such as cancer, diabetes, and cardiovascular diseases are major public health concerns worldwide. Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases. The advancements in genetic engineering, cell therapy, and tissue engineering have significantly…
PR Newswire
08/12/2023

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in…

US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor.Acceptance triggers a first milestone payment. Further milestones are expected upon US and European launches which could now happen in 2Q24 in the US (FDA PDUFA 1action date: June 10, 2024) and 2H24 in Europe. These milestones total approximately...
Nasdaq GlobeNewswire
08/12/2023

ERRATUM: BioSenic on its way to find the necessary funds to perform its key…

PRESS RELEASE – INSIDE INFORMATION This is a corrected version of the original PR " BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease" published on December 6, 2023, 7am CEST where TrialCap Pte. Ltd., as part of the SPRIM Global Investments group (SGI), is named as the lender. Biosenic signs term sheet with TrialCap Pte. Ltd. for up to USD 8 million debt financing and USD 800,000 equity investment as a first...
Nasdaq GlobeNewswire
08/12/2023

CU Medicine study published in The Lancet Infectious Diseases concludes that a…

World's first large-scale study discovers an effective treatment for long COVID World's first large-scale study discovers an effective treatment for long COVID Long COVID refers to long-term symptoms involving multiple systems and organs that persist in recovered COVID-19 patients. Currently, it affects 40% of these patients worldwide, yet the mechanism remains unknown and effective treatment is lacking. The research team has previously shown that patients with long COVID lacked a...
PR Newswire
08/12/2023

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise…

Being led by an international team of clinical researchers, the study's Principal Investigator Dr. Sophie McGrath, a Consultant Medical Oncologist at the Royal Marsden Foundation Trust, commented, "RELATE-2 represents a new way to assess patient experiences in the real world, using a widely available, clinically-validated, cancer patient support app. I'm looking forward to gaining a detailed understanding of how patients experience the use of new treatment-specific support apps countrywide…
PR Newswire
08/12/2023

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at…

Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report Discover which therapies are expected to grab the major chronic rhinosinusitis with nasal polyps market share @Chronic Rhinosinusitis with Nasal Polyps Market Report Chronic Rhinosinusitis with Nasal Polyps Overview Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts...
PR Newswire
07/12/2023

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 44 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 7, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
07/12/2023

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new…

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C. To register as an in-person attendee,please click here. To register as a virtual attendee,...
Nasdaq GlobeNewswire
07/12/2023

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 43 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, December 7, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 47,077 divided into 47,077 new shares with a nominal value of DKK 1...
Nasdaq GlobeNewswire
07/12/2023

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 November 202383,814,526Gross...
Nasdaq GlobeNewswire
07/12/2023

Functional Service Provider (FSP) Clinical Research Organization (CRO) Market…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-21T7736/Global_Functional_Service_Provider_FSP_Clinical_Research_Organization Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-21T7736/Global_Functional_Service_Provider_FSP_Clinical_Research_Organization Major Factors Driving the Growth of the FSP CRO Market: A number of factors, such as the growing complexity of clinical trials, the desire for cost-efficiency and...
PR Newswire
07/12/2023

AI In Mental Health Market worth US$ 10.93 Billion by 2031 - Exclusive Report by…

AI In Mental Health Market Report Scope AI In Mental Health Market Report Scope Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1272 With the emergence of digital methods for mental health, current artificial intelligence (AI) (machine learning in particular) is being utilized to build mental health care solutions for prediction, detection, and therapy. Despite major advancements in digital health and the application of AI to physical health in...
PR Newswire
07/12/2023

Clinical Trial Investigative Site Network Market worth US$ 14.25 Billion by 2031…

Clinical Trial Investigative Site Network Market Report Scope Clinical Trial Investigative Site Network Market Report Scope Request for Sample Pages:https://www.insightaceanalytic.com/request-sample/1486 Clinical investigational site networks are a collection of independent clinical sites that meet particular qualifying criteria and work as a single entity. This could be a new strategy for reducing the rise in R&D expenses. The idea that these sites are independently...
PR Newswire
07/12/2023

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 7 December 2023 at 7.00 p.m. (EET)BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes OyjLEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number:...
Nasdaq GlobeNewswire
07/12/2023

Coloplast A/S - Change of auditor

/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S' auditors in line with the proposal from the Board of Directors.For further information, please contactInvestors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor...
Nasdaq GlobeNewswire
07/12/2023

Coloplast A/S - Articles of Association

Articles of association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 7 December 2023 are enclosed. For further information, please contactInvestors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: dkadim@coloplast.com Kristine Husted Munk Senior Manager, Investor Relations Tel. +45 4911 1800 / +45…
Nasdaq GlobeNewswire
07/12/2023

Coloplast A/S - Decisions at the Annual General Meeting 2023

/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2022/23 was approved.Distribution of year-end dividend of DKK 16 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S' half-year result, this brings the total dividend paid for the financial year 2022/23 to DKK 21.00 per share of nominally DKK 1.The...
Nasdaq GlobeNewswire
07/12/2023

Sanitary Ware Market to Reach $15.9 Billion, Globally, by 2032 at 6.1% CAGR…

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/3841 Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/3841 Prime determinants of growth The sanitary ware market is primarily driven by remodeling and renovation initiatives. However, the market for sanitary ware is significantly constrained by high installation costs. On the other hand, smart technology integration is creating lucrative opportunities for the...
PR Newswire
07/12/2023

Antibody Therapeutics Market Worth $479.0 Billion | MarketsandMarkets

313 - Tables 313 - Tables 51 - Figures 306 - Pages Antibody Therapeutics Market Scope: Monoclonal antibodies subsegment is the fastest-growing of the antibody therapeutics market by format. Among the format subsegments, the antibody therapeutics market is segmented into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and other novel antibody therapies. In 2022, the monoclonal antibodies segment accounted for the fastest-growing...
PR Newswire
07/12/2023

Corporate Wellness Market Size to Grow USD 73640 Million by 2029 at a CAGR of…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-0B6365/Global_Corporate_Wellness_Market Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-0B6365/Global_Corporate_Wellness_Market Major Factors Driving the Growth of the Corporate Wellness Market : The Corporate Wellness Market is enjoying substantial expansion driven by a confluence of factors. Employers, understanding the crucial importance of employee well-being in...
PR Newswire
07/12/2023

U.S. Dental Services Market Size Estimated to Reach USD 254.09 Billion by 2032 |…

Forecasted U.S. Dental Services Market Size and Y-O-Y from 2022 to 2032 Forecasted U.S. Dental Services Market Size and Y-O-Y from 2022 to 2032 U.S. Dental Services Market Revenue ($ Billion), By Services U.S. Dental Services Market Revenue ($ Billion), By Application The Full Study is Readily Available | Download the Sample Pages of this Report@https://www.precedenceresearch.com/sample/1425 The dental services refer to maintaining oral hygiene. Dental...
PR Newswire
07/12/2023

If you hear beeps that last, get out fast - Kidde launches new campaign showing…

Kidde is teaming up with Myleene Klass, the author of 'They don't teach this at school' and fire safety advocate, to help educate families and children on the importance of having working smoke alarms and practising fire safety at home. Kidde recognises the need for a creative approach to help children easily recall what to do in the event of a fire, by introducing the Cause For Alarm jingle, "Beeps That Last, Get Out Fast" (https://bit.ly/46mQ9tg). Kidde is teaming up with Myleene…
PR Newswire
07/12/2023

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16%…

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386 Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386 Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services. With advancements in medical technology, there is a growing trend towards personalized medicine, where treatments are tailored to individual patients based on...
PR Newswire
07/12/2023

Bugworks Research Inc. to Present Poster at the European Society for Medical…

Bugworks Research is at the forefront of developing novel small molecule drugs to combat hard-to-treat cancers and drug-resistant bacterial infections. The company is building a deep pipeline of differentiated oncology programs that target critical pathways involved in cancer progression and treatment evasion. Bugworks Research is at the forefront of developing novel small molecule drugs to combat hard-to-treat cancers and drug-resistant bacterial infections. The company is building a deep...
PR Newswire
07/12/2023
Altri  Comunicati